Keep the result and its context together.
A performance number is useful only when the team can explain what was evaluated, on which data, against which reference standard and for which intended clinical use.
Those connections become more valuable as products, models and teams change. A clinical validation record should let another reviewer reconstruct the question and the work behind the answer.
Four connections to preserve
- Record the intended clinical use and the evidence question the study answers.
- Link the evaluated model, dataset, expert reference and configuration to the resulting analysis.
- Retain decisions and their rationale so the team can revisit the evidence when the product or context changes.
- Treat clinical validation as one part of the manufacturer’s broader quality system.
When something changes, revisit the evidence.
Identify the affected version, population, workflow and acceptance criteria. Record which evidence remains relevant, what needs further evaluation and who owns the next decision. Monitoring should feed that review with an agreed response path.
Use the Signal change receipt →
The quality-system context
FDA’s Quality Management System Regulation became effective February 2, 2026. Clinical validation is one part of the manufacturer’s broader quality system; a linked evidence record does not replace those wider responsibilities.
Primary regulatory source: FDA QMSR overview ↗. This article is operational commentary, not FDA guidance.